KINSLEY BONFILIO: Open Payments
NPI 1801567110 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,035 in 55 payments from 14 companies in 2025. Trend: 2023 $1,184 · 2024 $1,325 · 2025 $1,035
Food & beverage: $1,035
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 12 | $176 |
| AstraZeneca Pharmaceuticals LP | 7 | $130 |
| Novartis Pharmaceuticals Corporation | 5 | $126 |
| Regeneron Healthcare Solutions, Inc. | 6 | $110 |
| Grifols USA, LLC | 5 | $109 |
| Organon LLC | 5 | $96 |
| CSL Behring | 4 | $80 |
| Amgen Inc. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Blueprint Medicines Corporation | 2 | $36 |
Products named: TRELEGY ELLIPTA, Prolastin-C Liquid, DUPIXENT, TEZSPIRE, Rhapsido, AIRSUPRA, Hizentra, VTAMA.
Industry payments across ID — which companies pay providers there.
